ELTX

Elicio Therapeutics Inc.

NASDAQ: ELTX · HEALTHCARE · BIOTECHNOLOGY

$2.89

-2.03% today

Updated 2026-07-29

Market cap

$78.79M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.25

Dividend yield

—

52W range

$3 – $16

Volume

2.0M

Market cap

$78.79M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.25

Dividend yield

—

52W range

$3 – $16

Volume

2.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-17.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$20.00

+592.04%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity -9.98x — low leverage

Risks

- Altman Z -16.99 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-11.64M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-28.21M	$-35.20M	$-51.90M	$-39.57M	$-11.82M
EPS	—	—	—	—	$-2.25
Free cash flow	$-22.83M	$-32.76M	$-37.16M	$-36.97M	$-11.64M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ELTX	$78.79M	17	4.3	3.0	5.0	6.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Elicio Therapeutics Inc. trades at $2.89. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -16.99, it sits in the distress.

Frequently asked questions

What is Elicio Therapeutics Inc.'s stock price?

Elicio Therapeutics Inc. (ELTX) trades at $2.89.

Is Elicio Therapeutics Inc. overvalued?

Elicio Therapeutics Inc. carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Elicio Therapeutics Inc. (ELTX)?

The 12-month analyst consensus target is $20.00, about 592.0% above the current $2.89. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Elicio Therapeutics Inc.'s Altman Z-Score is -16.99, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-1,076.00%

Beta1.79

50D MA$7.16

200D MA$9.02

Shares out0.03B

Float0.01B

Short ratio—

Avg volume2.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ELTX vs LLY →ELTX vs JNJ →ELTX vs ABBV →Stock screener →